Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloRelapseMM
NCT05675319Phase 3Terminated
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of allogeneic stem cells in multiple myeloma (MM) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Overall Survival at 5 years. Started Mar 2023; status: terminated.
02
Drugs
allogeneic stem cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05675319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05675319.